Figure 5 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib

<jats:p>&lt;p&gt;SLFN11 expression in multiple myeloma (MM) cell lines and SLFN11 translocation to nucleoli by BTZ. &lt;b&gt;A,&lt;/b&gt; Correlation between the expression of &lt;i&gt;SLFN11&lt;/i&gt; and &lt;i&gt;SLFN13&lt;/i&gt; in the Cancer Therapeutics Response Portal (CTRP)–Broad–MIT cell line database (&lt;a href="https://discover.nci.nih.gov/cellminercdb/" target="_blank"&gt;https://discover.nci.nih.gov/cellminercdb/&lt;/a&gt;). Correlation coefficient and &lt;i&gt;P&lt;/i&gt; value are indicated above the figure. &lt;b&gt;B,&lt;/b&gt; Representative SLFN11 immunoblots in MM.1S, KMS-34, and KMS-27 cell lines. Human osteosarcoma cell line U2OS was used as a negative control. &lt;b&gt;C,&lt;/b&gt; Scheme of the nucleolus comprising the fibrillar center, the dense fibrillar component, and the granular component. &lt;b&gt;D,&lt;/b&gt; Representative immunofluorescence images showing total SLFN11 (green, left, no preextraction) and chromatin-bound SLFN11 (green, right) with nucleolin (red) and DAPI (blue) in MM.1S and KMS-34 cells after 4-hour treatment with BTZ [0.5 μmol/L (MM.1S), 5 μmol/L (KMS-34)] or CPT [1 μmol/L (MM.1S), 5 μmol/L (KMS-34)]. Scale bars, 10 μm. &lt;b&gt;E,&lt;/b&gt; Representative immunofluorescence images showing total chromatin-bound SLFN11 (green) with UBF (red) and DAPI (blue) in KMS-34 cells after 4-hour treatment. Scale bars, 10 μm. &lt;b&gt;F,&lt;/b&gt; Representative immunofluorescence image showing BTZ-induced SLFN11 nucleolar translocation in U2OS with DOX-inducible SLFN11 expression. Cells were treated with CPT or BTZ (1 μmol/L) for 4 hours.&lt;/p&gt;</jats:p>